Infanrix-Ipv+hib

Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate) and inactivated poliovirus type 3, the active ingredients in Infanrix‑Ipv+Hib, are vaccines presented as an injectable solution for intramuscular use. They protect infants and children against diphtheria, tetanus, pertussis, poliomyelitis and Hib disease.

GNH USA supplies Infanrix‑Ipv+Hib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix‑Ipv+Hib is a combination vaccine that targets bacterial and viral pathogens responsible for serious childhood infections. - Diphtheria: induces protective antibodies against diphtheria toxin. - Tetanus: stimulates immunity to tetanus toxin. - Pertussis: prevents whooping cough by generating antibodies to pertussis antigens. - Poliomyelitis: provides immunity to poliovirus types 1‑3. - Haemophilus influenzae type b: prevents invasive Hib disease by targeting the capsular polysaccharide.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Irritability: increased fussiness in infants. - Loss of appetite: temporary decrease in feeding. - Headache: mild headache reported in some recipients.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare occurrence, especially in febrile infants. - High fever (>40 °C): may indicate systemic reaction. - Severe allergic reaction: including angioedema or urticaria. - Guillain‑Barré syndrome: extremely rare demyelinating disorder. - Persistent neurological symptoms: prolonged irritability or abnormal movements.

Infanrix‑Ipv+Hib should be administered according to national immunisation schedules and under professional supervision. - Contraindication: severe allergic reaction to any vaccine component. - Postpone vaccination: moderate or severe acute illness with fever. - Monitor: observe for fever or local reactions for at least 15 minutes post‑injection. - Caution: use with care in immunocompromised children, as response may be reduced. - Avoid: simultaneous administration with live vaccines within 4 weeks. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Infanrix‑Ipv+Hib may interact with other agents that affect immune response. Major Interactions (Avoid): - Immunoglobulin therapy: can diminish vaccine‑induced immunity. - Live vaccines given within 4 weeks: may interfere with immune response. - High‑dose steroids or immunosuppressants: may reduce antibody production. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may mask post‑vaccination fever. - Concurrent injectable vaccines: generally safe but monitor for increased reactogenicity.